RT Journal Article
SR Electronic
T1 Maternal and Fetal Pharmacokinetic Analysis of Cannabidiol during Pregnancy in Mice
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 337
OP 343
DO 10.1124/dmd.120.000270
VO 49
IS 4
A1 Ochiai, Wataru
A1 Kitaoka, Satoshi
A1 Kawamura, Taisuke
A1 Hatogai, Jo
A1 Harada, Shohei
A1 Iizuka, Misa
A1 Ariumi, Mashu
A1 Takano, Seiya
A1 Nagai, Tomomi
A1 Sasatsu, Masanaho
A1 Sugiyama, Kiyoshi
YR 2021
UL http://dmd.aspetjournals.org/content/49/4/337.abstract
AB Cannabidiol (CBD), a major component of cannabis, has various effects, such as antiemetic and anxiolytic activities, and has recently been marketed as a supplement. The number of people using CBD during pregnancy is increasing, and there are concerns about its effects on the fetus. In addition, the scientific evidence supporting the fetal safety of CBD use during pregnancy is insufficient. To investigate CBD transfer from the mother to the fetus, a single intravenous dose of CBD was administered to pregnant mice in this study, and fetal pharmacokinetics (distribution and elimination) was analyzed. The transfer of CBD from the maternal blood to the fetus was rapid, and the compound accumulated in the fetal brain, liver, and gastrointestinal tract. Conversely, little CBD was transferred from the mother to the amniotic fluid. We analyzed the pharmacokinetics of CBD using a two-compartment model and found that the maternal and fetal half-lives of CBD were approximately 5 and 2 hours, respectively. Furthermore, we performed a moment analysis of the pharmacokinetics of CBD, observing a mean residence time of less than 2 hours in both the mother and fetus. These results suggest that once-daily CBD intake during pregnancy is unlikely to result in CBD accumulation in the mother or fetus.SIGNIFICANCE STATEMENT CBD is currently marketed as a supplement, and despite its increasing use during pregnancy, little information concerning its fetal effects has been reported. In the present study, CBD was administered to pregnant mice, and the pharmacokinetics in the fetus was investigated using a two-compartment model and moment analysis. The results of these analyses provide important information for estimating the risk to the fetus if CBD is mistakenly consumed during pregnancy.